Article Sidebar
Keywords:
obesity metabolic syndrome adiponectin
Article Details
Issue
Section
Articles
Material submitted for publication in the South African Journal of Clinical Nutrition (SAJCN) is accepted provided it has not been published elsewhere. Copyright forms will be sent with acknowledgement of receipt and the SAJCN reserves copyright of the material published.
The SAJCN does not hold itself responsible for statements made by the authors.
Main Article Content
Adiponectin could be a comprehensive marker of metabolic syndrome in obese children
Abstract
Objectives: The objectives were to investigate the relationship between the serum adiponectin level and the metabolic syndrome (MS) phenotype in children, and to examine the independent association between the serum adiponectin level and the individual components of MS.
Design: A cross-sectional design was used.
Subjects: Fifty-six obese children with a body mass index ≥ 95th percentile for age and sex, and 50 normal-weight children matched for age and sex with the obese children, were used as controls.
Outcome measures: The main outcome measure was the serum adiponectin level.
Results: The serum adiponectin level was significantly lower in obese children, than in the normal-weight controls (7.35 ± 3.1 μg/dl vs. 10.64 ± 3.04 μg/dl). Obese children with MS have a significantly lower serum adiponectin level compared to obese children without MS (5.92 ± 1.9μg/dl vs. 8.57 ± 2.1 μg/dl). There was a significant negative correlation between the serum adiponectin level and waist circumference, triglyceride levels, systolic blood pressure, diastolic blood pressure, and fasting blood glucose. The serum adiponectin level correlated positively with the level of high-density lipoprotein cholesterol. After controlling for the confounding effect of age, sex and visceral fat, the adiponectin level remained a significant predictor of the MS [odds ratio (OR): 0.76, 95% CI: 0.63-0.91].
Conclusion: Adiponectin demonstrated a consistent relationship to each MS component. Adiponectin may be a comprehensive marker of the MS condition.
Design: A cross-sectional design was used.
Subjects: Fifty-six obese children with a body mass index ≥ 95th percentile for age and sex, and 50 normal-weight children matched for age and sex with the obese children, were used as controls.
Outcome measures: The main outcome measure was the serum adiponectin level.
Results: The serum adiponectin level was significantly lower in obese children, than in the normal-weight controls (7.35 ± 3.1 μg/dl vs. 10.64 ± 3.04 μg/dl). Obese children with MS have a significantly lower serum adiponectin level compared to obese children without MS (5.92 ± 1.9μg/dl vs. 8.57 ± 2.1 μg/dl). There was a significant negative correlation between the serum adiponectin level and waist circumference, triglyceride levels, systolic blood pressure, diastolic blood pressure, and fasting blood glucose. The serum adiponectin level correlated positively with the level of high-density lipoprotein cholesterol. After controlling for the confounding effect of age, sex and visceral fat, the adiponectin level remained a significant predictor of the MS [odds ratio (OR): 0.76, 95% CI: 0.63-0.91].
Conclusion: Adiponectin demonstrated a consistent relationship to each MS component. Adiponectin may be a comprehensive marker of the MS condition.
